Back to Browse Journals » Clinical Ophthalmology » Volume 2 » Issue 1

Clinical treatment options for patients with homonymous visual field defects

Authors Alison R Lane, Daniel T Smith, Thomas Schenk

Published Date March 2008 Volume 2008:2(1) Pages 93—102

DOI http://dx.doi.org/10.2147/OPTH.S2371

Published 17 March 2008

Alison R Lane, Daniel T Smith, Thomas Schenk

Cognitive Neuroscience Research Unit, Durham University, Durham, UK

Abstract: The objective of this review is to evaluate treatments for homonymous visual field defects (HVFDs). We distinguish between three treatments: visual restoration training (VRT), optical aids, and compensatory training. VRT is both the most ambitious and controversial approach, aiming to restore portions of the lost visual field. While early studies suggested that VRT can reduce the visual field defect, recent studies using more reliable means of monitoring the patients’ fixation could not confirm this effect. Studies utilizing modern optical aids have reported some promising results, but the extent to which these aids can reliably reduce the patients’ visual disability has yet to be confirmed. Compensatory approaches, which teach patients more effective ways of using their eyes, are currently the only form of treatment for which behavioral improvements have been demonstrated. However, with the exception of one study using a reading training, placebo-controlled clinical evaluation studies are lacking. It is also not yet clear whether the training benefits found in laboratory tasks lead to reliable improvements in activities of daily living and which of the various forms of compensatory training is the most promising. It is therefore too early to recommend any of the currently available treatment approaches.

Keywords: homonymous hemianopia, rehabilitation, treatment outcome

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Nanomedicine strategies for treatment of secondary spinal cord injury

White-Schenk D, Shi R, Leary JF

International Journal of Nanomedicine 2015, 10:923-938

Published Date: 29 January 2015

Nanocomplexation of thrombin with cationic amylose derivative for improved stability and hemostatic efficacy

Zhuang B, Li Z, Pang J, Li W, Huang P, Wang J, Zhou Y, Lin Q, Zhou Q, Ye X, Ye H, Liu Y, Zhang LM, Chen R

International Journal of Nanomedicine 2015, 10:939-947

Published Date: 29 January 2015

Real-world effectiveness of amlodipine/valsartan and amlodipine/valsartan/hydrochlorothiazide in high-risk patients and other subgroups

Assaad-Khalil SH, Najem R, Sison J, Kitchlew AR, Cho BL, Ueng KC, DiTommaso S, Shete A

Vascular Health and Risk Management 2015, 11:71-78

Published Date: 21 January 2015

Bio-functionalized dense-silica nanoparticles for MR/NIRF imaging of CD146 in gastric cancer

Wang P, Qu Y, Li C, Yin L, Shen C, Chen W, Yang S, Bian X, Fang D

International Journal of Nanomedicine 2015, 10:749-763

Published Date: 20 January 2015

Chloronychia: green nail syndrome caused by Pseudomonas aeruginosa in elderly persons

Chiriac A, Brzezinski P, Foia L, Marincu I

Clinical Interventions in Aging 2015, 10:265-267

Published Date: 14 January 2015

Photothermal cancer therapy using graphitic carbon–coated magnetic particles prepared by one-pot synthesis

Lee HJ, Sanetuntikul J, Choi ES, Lee BR, Kim JH, Kim E, Shanmugam S

International Journal of Nanomedicine 2015, 10:271-282

Published Date: 30 December 2014

Using registries to identify type 2 diabetes patients

Thomsen RW, Sørensen HT

Clinical Epidemiology 2015, 7:1-3

Published Date: 18 December 2014

Intracameral phenylephrine and ketorolac injection (OMS302) for maintenance of intraoperative pupil diameter and reduction of postoperative pain in intraocular lens replacement with phacoemulsification

Lindstrom RL, Loden JC, Walters TR, Dunn SH, Whitaker JS, Kim T, Demopulos GA, Tjia K

Clinical Ophthalmology 2014, 8:1735-1744

Published Date: 5 September 2014

Evaluation of in vitro glistening formation in hydrophobic acrylic intraocular lenses

Thomes BE, Callaghan TA

Clinical Ophthalmology 2013, 7:1529-1534

Published Date: 25 July 2013

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010